

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)

Approved for use through 07/31/2016. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	PARK		
	Art Unit			
	Examiner Name			
	Attorney Docket Number		4240-651	

U.S. PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.								
U.S. PATENT APPLICATION PUBLICATIONS								
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.								
FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2011512844	JP	A	2011-04-28	Baker, D., et al.		☐
	2	2011512844	JP	A	2011-04-28	Baker, D., et al.	ENGLISH TRANSLATION	☒
	3	2020022791	WO	A1	2020-01-30	Park, SJ, et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	PARK		
	Art Unit			
	Examiner Name			
	Attorney Docket Number		4240-651	

	4	2020022791	WO	A1	2020-01-30	Park, SJ, et al.	ENGLISH TRANSLATION	☒
--	---	------------	----	----	------------	------------------	------------------------	-------------------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Office Action Issued in Japanese Patent Application No. 2022559471 on October 11, 2023	☐
	2	English Translation of Office Action Issued in Japanese Patent Application No. 2022559471 on October 11, 2023	☒

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	PARK
	Art Unit	
	Examiner Name	
	Attorney Docket Number	4240-651

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☒ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/steven j. hultquist/	Date (YYYY-MM-DD)	2023-11-03
Name/Print	Steven J. Hultquist	Registration Number	28021

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1	5721348		1998-02-24	Primakoff et al.			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1	20130101577	A9	2013-04-25	Wei et al.			
	2	20170089914	A1	2017-03-30	Loo et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	22752	EA	B1	2016-02-29	HALOZYME INC.		☐
	2	10-2021-0023798	KR	A	2021-03-04	Alteogen, Inc		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	3	10-2020-0130451	KR	A	2020-11-18	Alteogen, Inc		☒
	4	10-2017-0065032	KR	A	2017-06-12	HALOZYME, INC		☒
	5	10-2022-0069045	KR	A	2022-05-26	Alteogen, Inc		☒
	6	2018204368	WO		2018-08-11	Merck Sharp & Dohme		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	CN201980023392.4 - Decision of Final Rejection mailed on May 17, 2024, 10 pages.	☒
	2	CA3,093,885 - Office Action mailed on June 3, 2024, 4 pages.	☐
	3	JP2022-211105 - Decision of Rejection mailed on May 14, 2024, 3 pages.	☒
	4	H. Johansen, ET AL., "High-level production of fully active human alpha 1-antitrypsin in Escherichia coli." Mol. Biol. Med. (1987) Volume 4, Page(s) 291-305.	☐
	5	J.H. Dunham, ET AL., "GPR37 Surface Expression Enhancement via N-Terminal Truncation or Protein-Protein Interactions", Biochemistry (2009) 48, Page(s) 10286-10297.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

6	M. Wei, ET AL., "N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro", Emerging Microbes & Infections (2018) Volume 7, Page(s) 160.	☐
7	M. F. Meyer, ET AL., "The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme", FEBS letter (1997) Volume 413, Page(s) 385-388.	☐
8	International Search Report and Written Opinion dated September 21, 2023 in International Application No. PCT/KR2023/008621, Pages 15.	☒
9	AU2021320569 - Examination Report No. 1 mailed on April 30, 2024, 3 pages.	☐
10	CA3,131,052 - Office Action mailed on May 6, 2024, 5 pages.	☐
11	CN2021800300979 - First Office Action mailed on January 6, 2024, 18 pages.	☒
12	MX/a/2020/009824 - Office Action mailed on June 10, 2024, 16 pages.	☒
13	TW111145281 - First Office Action mailed on May 29, 2024, 16 pages.	☒
14	TW111128188 - First Office Action mailed on May 29, 2024, 24 pages.	☒
15	TW110102662 - Office Action mailed on May 3, 2024, 22 pages.	☒
16	TW111136059 - Office Action mailed on May 3, 2024, 20 pages.	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

	17	JP2022211105 - Notice of Reasons for Refusal mailed on November 14, 2023, 17 pages.	☒
	18	CN201980023392.4 - First Office Action mailed on June17, 2023, 9 pages.	☒
	19	KR20207002955 - Written Decision on Registration mailed on August 25, 2020, 16 pages.	☒
	20	JP2020500863 - Notice of Reasons for Refusal mailed on January 25, 2022, 7 pages.	☒
	21	JP2020500863 - Notice of Reasons for Refusal mailed on May 24, 2022, 6 pages.	☒
	22	JP2020500863 - Notice of Reasons for Refusal mailed on June 15, 2021, 12 pages.	☒
	23	EP19827585 - Supplementary European search report mailed on March 31, 2021, 9 pages.	☐
	24	JP2022211105 - Decision of Rejection mailed on May 14, 2024, 2 pages.	☒
	25	CA3,093,885 - Examiner Requisition mailed on September 01, 2021, 4 pages.	☐
	26	CA3,093,885 - Examiner Requisition mailed on October 03, 2022, 6 pages.	☐
	27	AU2019311658 - Examination Report No. 1 mailed on June 17, 2022, 3 pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

	28	AU2019311658 - Notice of Acceptance mailed on October 11, 2022, 3 pages.	☐
	29	Bazhenova et al., Cancer Research, Vol. 77, No. 13, suppl. Abstract No. CT032	☐
	30	US17/052,952 - Non-Final Office Action mailed on June 13, 2024, 20 pages.	☐
	31	KR20227013211 - Request for the Submission of an Opinion mailed on April 26, 2024, 7 pages.	☒
	32	CN202180003323.4 - First Office Action mailed on November 27, 2023, 14 pages.	☒
	33	EP21743774 - Supplementary European search report mailed on January 4, 2023, 20 pages.	☐
	34	JP2021567961 - Decision of Rejection mailed on November 14, 2023, 8 pages.	☒
	35	JP2021567961 - Notice of Reasons for Refusal mailed on April 11, 2023, 6 pages.	☒
	36	AU2021211348 - Examination Report No. 1 mailed on March 17, 2023, 3 pages.	☐
	37	AU2021211348 - Examination Report No. 2 mailed on July 11, 2023, 5 pages.	☐
	38	AU2021211348 - Notice of Acceptance mailed on September 21, 2023, 4 pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

	39	CA3,137,324 - Examiner Requisition mailed on December 2, 2022, 4 pages.	☐
	40	CA3,137,324 - Examiner Requisition mailed on May 6, 2024, 6 pages.	☐
	41	KR20207030248 - Written Decision on Registration mailed on December 22, 2023, 5 pages.	☒
	42	KR20207030248 - Notice of Final Rejection mailed on July 27, 2023, 6 pages.	☒
	43	KR20207030248 - Request for the Submission of an Opinion mailed on August 28, 2022, 14 pages.	☒
	44	KR20227016935 - Written Decision on Registration mailed on December 21, 2022, 6 pages.	☒
	45	JP2022068166 - Notice of Reasons for Refusal mailed on June 21, 2022, 8 pages.	☒
	46	JP2022068166 - Decision to Grant a Patent mailed on October 4, 2022, 5 pages.	☒
	47	JP2020569741 - Notice of Reasons for Refusal mailed on November 16, 2021, 8 pages.	☒
	48	JP2020569741 - Decision to Grant a Patent mailed on May 16, 2023, 5 pages.	☒
	49	CN202310416462.0 - Notification of grant of patent right for invention mailed on May 16, 2024, 3 pages.	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

50	AU2020248612 -Examination Report No. 3 mailed on November 8, 2023, 2 pages.	☐
----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mincheol Kim/	Date (YYYY-MM-DD)	2024-07-22
Name/Print	Mincheol Kim	Registration Number	51,306

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2012135408	WO	A	2012-04-10	MERCK SHARP & DOHME		☐
	2	7166478	JP	B2	2022-07-11	ALTEOGEN INC.		☒
If you wish to add additional Foreign Patent Document citation information please click the Add button.							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AU2020248612 -Examination Report No. 2 mailed on October 25, 2023, 3 pages.	☐
	2	CA3,131,052 -Office Action mailed on May 6, 2024, 5 pages.	☐
	3	EP20776465.5 - Extended European search report mailed on February 11, 2022, 15 pages.	☐
	4	KR20210103530 - Request for the Submission of an Opinion mailed on September 19, 2023, 7 pages.	☒
	5	RU2022125351 - Office Action mailed on November 2, 2023, 15 pages.	☒
	6	International Search Report and Written Opinion dated November 18, 2021 in International Application No. PCT/KR2021/010368, Pages 17.	☒
	7	RU2021132331 - Decision of grant mailed on November 3, 2023, 16 pages.	☒
	8	AU2020248612 - Notice of Acceptance mailed on September 21, 2023, 4 pages.	☐
	9	JP2022211105 - Decision of Dismissal of Amendment mailed on May 14, 2024, 4 pages.	☒
	10	JP2021567961 - Office Action mailed on July 2, 2024, 6 pages.	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

	11	CN202180003323.4 - Office Action mailed on July 10, 2024, 12 pages.	☒
	12	Tavares, A. et al., "Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry", Scientific Reports, Volume 8, Issue 1840, pp 1-13.	☐
	13	CONC20210012380 - Office Action mailed on January 11, 2024, 16 pages.	☒
	14	EA202192588 - Office Action mailed on September 29, 2023, 8 pages.	☒
	15	IDP00202108509 - Office Action mailed on September 27, 2023, 4 pages.	☒
	16	PA93644-01 - Search Report mailed on March 29, 2022, 8 pages.	☒
	17	VN1-2021-06635 - Office Action mailed on February 26, 2024, 3 pages.	☒
	18	US16/628,258 - Notice of Allowance mailed on July 16, 2024, 8 pages.	☐
	19	US17/608,729 - Requirement for Restriction/Election mailed on May 14, 2024, 5 pages.	☐
	20	Appendix A Sequence Alignment, 2024.	☐
	21	Office Action dated July 9, 2021 in Taiwanese Patent Application No. 109119328	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

If you wish to add additional non-patent literature document citation information please click the Add button Add			
EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mincheol Kim/	Date (YYYY-MM-DD)	2024-07-22
Name/Print	Mincheol Kim	Registration Number	51,306

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: RCEX

Doc description: Request for Continued Examination (RCE)

PTO/SB/30EFS (01-22)

Approved for use through 05/31/2024. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL
(Submitted Only via EFS-Web)**

Application Number	17/907,538	Filing Date	2022-09-27	Docket Number (if applicable)	1959690.00014/ALTEO.12NP	Art Unit	1652
First Named Inventor	Soon Jae PARK			Examiner Name	Christian L FRONDA		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV**SUBMISSION REQUIRED UNDER 37 CFR 1.114**

Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____☐ Other _____☒ Enclosed☒ Amendment/Reply☒ Information Disclosure Statement (IDS)☐ Affidavit(s)/ Declaration(s)☒ Other

Corrected ADS and Declaration

MISCELLANEOUS☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months _____
(Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)☐ Other _____**FEES****The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.**☒ The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to
Deposit Account No 021818**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**☒ Patent Practitioner Signature☐ Applicant Signature

Doc code: RCEX

Doc description: Request for Continued Examination (RCE)

PTO/SB/30EFS (01-22)

Approved for use through 05/31/2024. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner			
Signature	/Mincheol Kim/	Date (YYYY-MM-DD)	2024-07-22
Name	Mincheol Kim	Registration Number	51,306

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-22)

Approved for use through 05/31/2024. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

U.S.PATENTS Remove						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5854046	A	1998-12-29	Au-Young et al.	
	2	7767429	B2	2010-08-03	Bookbinder et al.	
	3	8105586	B2	2012-01-31	Bookbinder et al.	
	4	8202517	B2	2012-06-19	Bookbinder et al.	
	5	8257699	B2	2012-09-04	Bookbinder et al.	
	6	8288142	B2	2012-10-16	Uvarkina et al.	
	7	8431124	B2	2013-04-30	Bookbinder et al.	
	8	8580252	B2	2013-11-12	Bookbinder et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor		Soon Jae Park	
	Art Unit		1652	
	Examiner Name		CHRISTIAN L FRONDA	
	Attorney Docket Number		1959690.00014/ALTEO.12NP	

	9	8927249	B2	2015-01-16	Wei et al.	
	10	9211315	B2	2015-12-15	Bookbinder et al.	
	11	9284543	B2	2016-03-15	Wei et al.	
	12	9447401	B2	2016-09-20	Wei et al.	
	13	10286044	B2	2019-05-14	Bookbinder et al.	
	14	10328130	B2	2019-06-25	Frost et al.	
	15	10865400	B2	2020-12-15	Wei et al.	
	16	10918736	B2	2021-02-16	Kim et al.	
	17	11041149	B2	2021-06-22	Wei et al.	
	18	11066656	B2	2021-07-20	Wei et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20170218382	A1	2017-08-03	Akihiko KONDO; Akihiko	
	2	20210155913	A1	2021-05-27	Soon Jae PARK;	
	3	20110044977	A1	2011-02-24	Adler; Michael	
	4	20060104968	A1	2006-05-18	Bookbinder et al.	
	5	20100003238	A1	2010-01-07	Frost et al.	
	6	20120148535	A1	2012-06-14	Carrio et al.	
	7	20130302275	A1	2013-11-14	Wei et al.	
	8	20150165059	A1	2015-06-18	Bookbinder et al.	
	9	20180044419	A9	2018-02-15	Rosengren et al.	
	10	20180185506	A1	2018-07-05	Bookbinder et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	11	20190046657	A1	2019-02-14	Kim et al.	
	12	20220089738	A1	2022-03-24	Krishnamachari et al.	
	13	20220289864	A1	2022-09-15	Park et al.	
	14	20230174963	A1	2023-06-08	Park et al.	
	15	20230250408	A1	2023-08-10	Park et al.	
	16	20230365692	A1	2023-11-16	Krishnamachari et al.	
	17	20210363270	A1	2021-11-25	Park et al.	
	18	20150001529	A1	2015-01-01	Kurokawa, Y.	
	19	20170218069	A1	2017-08-03	Rosengren, S., et al.	
	20	20180250397	A1	2018-09-06	Benyunes, M.C., et al.	
	21	20140199282	A1	2014-07-17	Bookbinder, L., et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	22	20150010529	A1	2015-01-08	WEI GE	
	23	20100143457	A1	2010-06-10	Wei et al.	
	24	20160362670	A1	2016-12-15	Wei et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2009117085	WO	A1	2009-09-24	FROST G		☐
	2	2797622	EP	B1	2016-10-12	Halozyme Inc.		☐
	3	3130347	EP	B1	2019-09-18	Halozyme Inc.		☐
	4	2004078140	WO	A2	2004-09-16	Deliatroph Pharamceuticals, Inc.		☐
	5	2007064437	WO	A2	2007-06-07	Receptor Biologix Inc.		☐
	6	2009128917	WO	A2	2009-10-22	Halozyme Inc.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

	7	2010077297	WO	A1	2010-07-08	Halozyme Inc.		☐
	8	2015003167	WO	A1	2015-01-08	Halozyme Inc.		☐
	9	2016033555	WO	A1	2016-03-03	Halozyme Inc.		☐
	10	2018102372	WO	A1	2018-06-07	Memorial Sloan Kettering Cancer Center		☐
	11	2018183928	WO	A1	2018-10-04	Bristol Myers Squibb Co.		☐
	12	2018222722	WO	A2	2018-12-06	Bristol Myers Squibb Co.		☐
	13	2020172621	WO	A1	2020-08-27	Memorial Sloan Kettering Cancer Center		☐
	14	2021150079	WO	A1	2021-07-29	Alteogen Inc.		☒
	15	2022031093	WO	A1	2022-02-10	Alteogen Inc.		☒
	16	2023075506	WO	A1	2023-05-04	Alteogen Inc.		☒
	17	104244968	CN	A	2014-12-24	Halozyme Inc.		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	18	111971387	CN	A	2020-11-20	Alteogen Inc.		☒
	19	110494450	CN	A	2019-11-22	BRISTOL MYERS SQUIBB CO		☒
	20	2021011944	CO	A2	2021-09-30	MEMORIAL SLOAN KETTERING CANCER CENTER		☒
	21	2009515521	JP	A	2009-04-16	Jin, P., et al.		☒
	22	20120094493	KR	A	2012-08-24	Bookbinder, L., et al.		☒
	23	101363658	KR	B1	2014-02-10	HALOZYME, INC		☒
	24	1020160052812	KR	A	2016-05-12	HALOZYME, INC		☒
	25	101493644	KR	B1	2015-02-13	HALOZYME, INC		☒
	26	1020140021046	KR	A	2014-02-19	HALOZYME INC		☒
	27	1020100135291	KR	A	2010-12-14	HALOZYME INC		☒
	28	2013102144	WO	A2	2013-07-04	Wei, G., et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	29	1020130116386	KR	A	2013-10-23	Halozyme Inc.		☒
	30	2020197230	WO	A1	2020-01-10	Halozyme Inc.		☒
	31	2019222435	WO	A1	2019-11-21	Halozyme Inc.		☐
	32	102065886	CN	A	2011-05-18	Halozyme Inc.		☒
	33	101970650	CN	A	2011-02-09	Halozyme Inc.		☒
	34	102307993	CN	A	2012-01-04	Halozyme Inc.		☒
	35	101546563	KR	B1	2015-08-28	Halozyme Inc.		☒
	36	101233457	KR	B1	2013-02-15	Halozyme Inc.		☒
	37	1020200017538	KR	A	2020-02-18	Alteogen Inc		☒
	38	101874401	KR	B1	2018-07-04	Halozyme Inc.		☒
	39	1020200130451	KR	A	2020-11-18	Alteogen Inc		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538	
	Filing Date		2022-09-27	
	First Named Inventor	Soon Jae Park		
	Art Unit	1652		
	Examiner Name	CHRISTIAN L FRONDA		
	Attorney Docket Number	1959690.00014/ALTEO.12NP		

	40	1020120105426	KR	A	2012-09-25	BAXTER HEALTHCARE SA et al.		☒
	41	2011029892	WO	A2	2011-03-17	Adler, M., et al.		☐
	42	2017004706	WO	A1	2017-01-12	Drizen, K., et al.		☐
	43	2015071366	WO	A1	2015-05-21	Gonzalez, B., et al.		☐
	44	2017079150	WO	A1	2017-05-11	Jansson, R., et al.		☐
	45	2017131496	WO	A1	2017-08-03	Kim, D.J., et al.		☒
	46	2009065507	WO	A2	2009-05-28	Maggi, C.A., et al.		☐
	47	3785701	EP	A1	2021-03-03	Park, S.J., et al.		☐
	48	2020500863	JP	A	2020-01-16	Bloodberry, M.S., et al.		☒
	49	2015504666	JP	A	2015-02-16	Ge, W., et al.		☒
	50	2011012637	WO	A2	2011-02-03	Adler, M., et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

If you wish to add additional Foreign Patent Document citation information please click the Add button				Add
NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	
	1	Chan et al., "Therapeutic antibodies for autoimmunity and inflammation", Nature Reviews Immunology, Volume 10, May 2010, pages 301–316.	☐	
	2	Alley et al., "Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028", Journal of Thoracic Oncology, Abstract No. OA13.03, 2018, Vol. 12, No.1S, Page 1 (S294).	☐	
	3	LIMING LIU, "Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins", Protein Cell, 2018, Vol. 9, No.1, Pages 15-32.	☐	
	4	US17/052,952 - Non-Final Office Action mailed on December 12, 2023, 32 pages.	☐	
	5	International Search Report and Written Opinion mailed July 29, 2021 for International Patent Application No. PCT/KR2021/000943 filed March 24, 2020 (21 pages)	☐	
	6	International Search Report and Written Opinion mailed June 30, 2020 for International Patent Application No. PCT/KR2020/003975 filed March 24, 2020 (23 pages)	☒	
	7	International Search Report and Written Opinion mailed October 29, 2019 for PCT Application No. PCT/KR2019/009215 filed July 25, 2019 (21 pages)	☒	
	8	LIN et al. "Molecular cloning of the human and monkey sperm surface protein PH-20", Proc. Natl. Acad. Sci. November 1993, Vol 90, Pages 10071-10075.	☒	
	9	MCATEE, C., et al., "Emerging roles for hyaluronidase in cancer metastasis and therapy", "Advances in cancer research", 2014, Vol. 123, Pages 1-34.	☐	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

10	MULLER et al., "Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus", Arthritis & Rheumatism", December 2008, Vol. 58, Nb. 12, Pages 3873-3883.	☐
11	"Hyaluronidase PH-20 (Macaca nemestrina) NCBI Reference Sequence: XP011728213.1, April 24, 2018, Page 2.	☐
12	NCBI Reference Sequence: NP 001166492.1 ,hyaluronidase PH-20 precursor [Cavia porcellus], June 21 , 2021, Pages 2.	☐
13	NCBI Reference Sequence: NP 001166492.1 ,hyaluronidase PH-20 precursor [Cavia porcellus], June 19, 2020, Pages 2	☐
14	"PH-20 (Homo sapiens)", NCBI Genbank Accession No. AAC60607.2, June 5, 2000, page 1.	☐
15	WANG et al., "Antibody structure, instability, and formulation," Journal of pharmaceutical sciences., January 2007, Vol. 96, Nb.1, Pages 1-26.	☐
16	FROST and STERN, "A microtiter-based assay for hyaluronidase activity not requiring specialized reagents", "Analytical Biochemistry", 1997, Vol. 251, Pages 263-269.	☐
17	MARKOVIC-HOUSLEY et al., "Crystal structure of hyaluronidase, a major allergen of bee venom", "Structure", October, 2000, Vol. 8, , Pages 1025-1035.	☐
18	MESSINA et al., "Identification and characterization of a bacterial hyaluronidase and its production in recombinant form", "FEBS Letters", 2016, Volume 590, Issue 14, Pages 2180-2189.	☐
19	STERN and CSOKA, "Mammalian Hyaluronidases", "Glycoforum", 2000, Volume 4, Pages 1-6.	☐
20	LAFARO et al., "The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment", The American journal of pathology, Vol. 189, No.1, pages 44-57.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

21	PHILO et al., "A Critical Review of Methods for Size Characterization of Non-Particulate Protein Aggregates," J.S. Cur. Pharm. Biotech., 2009, vol. 10, 359-372	☐
22	TAKAHASHI, T. et al., "A fluorimetric Morgan-Elson assay method for hyaluronidase activity," Anal. Biochem., 2003, vol. 322, 257-263	☐
23	Office Action issued in Australian Patent Application No. 2020248612 on November 8, 2022, Pages 3.	☐
24	Office Action issued in Canadian Patent Application No. 3131052 on October 19, 2022, pages 6.	☐
25	US16/628,258 - Final Rejection mailed on March 12, 2024, 9 pages.	☐
26	US16/628,258 - Non-Final Office Action mailed on August 30, 2023, 13 pages.	☐
27	US16/628,258 - Requirement for Restriction/Election mailed on March 23, 2023, 9 pages.	☐
28	CA3137324 - Office Action mailed on May 6, 2024, 6 pages.	☐
29	SCHON, A., ET AL., "Denatured state aggregation parameters derived from concentration dependence of protein stability", Analytical Biochemistry, 2015, Page(s) 45-50, Volume 488, Publisher: Elsevier	☐
30	STERN and Jedrzejewski, "The Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action", "Chern Rev.", 2006, Pages 818-839, Volume 106, Number 3 with supplemental.	☐
31	CHAO, K., ET AL., "Structure of Human Hyaluronidase-1, a Hyaluronan Hydrolyzing Enzyme Involved in Tumor Growth and Angiogenesis", "Biochemistry", 2007, Page(s) 6911- 6920, Volume 46	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

	32	EESR Issued in counterpart European Patent Application No. 21743774.8 on January 4, 2023	☐
	33	BROUN, P., ET AL., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant D Lipids", SCIENCE, 1998, Pages 1315-1317, Volume 282, Number 13, Publisher: www.sciencemag.org	☐
	34	HIROMOTO, Y., ET AL., "An Activity-Straining Method on Filtration Paper Enables High-Throughput Screening of Temperature-Sensitive and Inactive Mutations of Rice -Amylase for Improvement of Rice Grain Quality", Plant and Cell Physiology, 2017, Pages 658-667, Volume 58, Number 4, Publisher: Japanese Society of Plant Physiologists	☐
	35	Office Action issued on December 2, 2022 in counterpart Canadian Patent Application No. 2137324, pages 4.	☐
	36	Office Action issued on October 17, 2022 in counterpart Russian Patent Application No. 2021132331, pages 18.	☒
	37	SEFFERNICK, J.L., ET AL., "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different", JOURNAL OF BACTERIOLOGY, 201, Pages 2405-2410, Volume 183, Number 8, Publisher: American Society for Microbiology	☐
	38	WHISSTOCK, J.D., ET AL., "Prediction of protein function from protein sequence and structure", Quarterly Reviews of Biophysics, 2003, Pages 307-340, Volume 36, Number 3, Publisher: Cambridge University Press	☐
	39	PAKULA, A., ET AL., "GENETIC ANALYSIS OF PROTEIN STABILITY AND FUNCTION", Annu. Rev. Genet., 1898, , Volume 23, Page(s) 289-310.	☐
	40	WITKOWSKI, A., ET AL., "Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine", Biochemistry, 1999, Volume 38, Publisher: American Chemical Society, Page (s) 11643-11650.	☐
	41	"GenBank: AAC6067.2, PH-20 (Homo sapiens)" , NCBI , June 5, 2000, Pages 2.	☐
If you wish to add additional non-patent literature document citation information please click the Add button Add			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mincheol Kim/	Date (YYYY-MM-DD)	2024-07-22
Name/Print	Mincheol Kim	Registration Number	51,306

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2662090	EP	A1	2013-11-13	Frost, G., et al.		☐
	2	3636752	EP	A1	2020-04-15	Park, S.J., et al.		☐
	3	201534726	TW	A	2015-09-16	HALOZYME INC		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

If you wish to add additional Foreign Patent Document citation information please click the Add button				Add
NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	
	1	International Search Report dated February 02, 2023 in International Application No. PCT/KR2022/016709, Pages 14.	☒	
	2	Strickley et al., "A review of formulations of commercially available antibodies", Journal of Pharmaceutical Sciences, 2021, Vol. 110, Pages 2590-2608.	☐	
	3	Zarrintaj et al., "Poloxamer: A versatile tri-block copolymer for biomedical applications", Acta Biomaterialia, 2020, Vol. 110, Pages 37-67.	☐	
	4	KR1020210103530 - Written Decision on Registration mailed on December 15, 2023, 6 pages.	☒	
	5	JP2022559471- Final Notification of Reasons for Refusal mailed on March 19, 2024, 8 pages.	☒	
	6	CN202180030097.9- First Office Action mailed on January 6, 2024, 19 pages.	☒	
	7	CA3173310- Office action mailed on December 20, 2023, 5 pages.	☐	
	8	CN201980023392.4 - Second Office Action mailed on February 08, 2024, 8 pages.	☒	
	9	NCBI Reference Sequence, hyaluronidase PH-20 precursor [Cavia porcellus], NP_001166492.1, June 21, 2021 Pages 2 (downloaded 8/24/2023).	☐	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		17907538
	Filing Date		2022-09-27
	First Named Inventor	Soon Jae Park	
	Art Unit	1652	
	Examiner Name	CHRISTIAN L FRONDA	
	Attorney Docket Number	1959690.00014/ALTEO.12NP	

10	Opposition dated July 5, 2022 by Asociacion de Laboratorios Farmaceuticos (ALAFAR) Against Ecuadorian Application No.SENADI-2021-70640, pages 3.	☒
11	Opposition filed January 13, 2022 by Laboratorios Legrand S.A. against Columbian Patent Application No. NC2021/0012380, pages 21.	☒
12	CN202310416462.0 - First Office Action mailed on March 05, 2024, 8 pages.	☒
13	CN202080003052.8 - Second Office Action mailed on March 02, 2024, 11 pages.	☒
14	CN202080003052.8 - First Office Action mailed on June 27, 2023, 12 pages.	☒
15	JP2023026863 - Notice of Reasons for Refusal mailed on March 12, 2024, 10 pages.	☒
16	KREIDIEH, F., ET AL., "Overview, Prevention and Management of Chemotherapy Extravasation", "World Journal of Clinical Oncology", 2/10/2016, Page(s) 87-97, Volume 7, Number 1.	☐
17	HOFINGER, E., ET AL., "Kinetics of Hyal-1 and PH-20 Hyaluronidases: Comparison of Minimal Substrates and Analysis of the Transglycosylation Reaction", "Glycobiology", 2007, Page(s) 963-971, Volume 17, Number 9.	☐
18	CHEN, K., ET AL., "Constitutive Expression of Recombinant Human Hyaluronidase PH20 by Pichia Pastoris", "Journal of Bioscience and Bioengineering", 2016, Page(s) 1-6	☐
19	BORDERS, C., ET AL., "Purification and Partial Characterization of Testicular Hyaluronidase", "The Journal of Biological Chemistry", 1968, Volume 243, Number 13, Page 3756-3762.	☐
20	SHPILBERG, O., ET AL., "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using D-thalidomide", "British Journal of Cancer", 2013, Volume 109, Page 1556-1561.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

21	BITTNER, B., ET AL., "Subcutaneous Administration of Biotherapeutics - An Overview of Current Challenges and Opportunities", BioDrugs, 2018, Volume 32, Publisher: CrossMark, Page 425-440.	☐
22	Opposition by LABORATORIOS LEGRAND S.A. Against Columbian Patent Application NC20210012380 with English Translation 10/20/2021, pages 21.	☒
23	Office Action issued in Saudia Arabia Patent Application No. 521430398 with English Translation on February 25, 2023, pages 11.	☒
24	Office Action issued in Chile Patent Application No. 202102464 with English Translation on May 4, 2023, pages 23.	☒
25	Opposition filed against Ecuador Patent Application SENADI-2021-70640 with English Translation on February 14, 2022, pages 217.	☒
26	Office Action issued in Korean Patent Application No. 20227016935 on August 28, 2022	☐
27	Office Action issued in Japanese Patent Application No. 2020569741 on August 23, 2022, 5 pages.	☒
28	Office Action issued in Georgian Patent Application No. AP202015767 with English Translation on April 3, 2023, pages 9.	☒

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	17907538
	Filing Date	2022-09-27
	First Named Inventor	Soon Jae Park
	Art Unit	1652
	Examiner Name	CHRISTIAN L FRONDA
	Attorney Docket Number	1959690.00014/ALTEO.12NP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mincheol Kim/	Date (YYYY-MM-DD)	2024-07-22
Name/Print	Mincheol Kim	Registration Number	51,306

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.